when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

1,576 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT806 Endpoints605 BioPharma Dive231 onclive165 Fierce Biotech74 BioSpace71 raps32 fda press20

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology

Anthony Fauci’s pandemic-era diary entries
New data on American substance use, concerns of a global HIV resurgence, and more health news from Morning Rounds
STAT · 22h agoRegulatoryNeutral↗ source
Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch
If the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total.
BioSpace · 23h agoRegulatoryNeutral↗ source

page 2 of 64

globenewswire health20

6

Infectious Disease4

Oak Hill takes SPAC track to Nasdaq with Roche asset in tow

Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.

BioSpace · 23h agoRegulatoryNeutral↗ source

After PCOS became PMOS, there’s hope for new awareness among Black and Latina women

Growing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high prevalence and low diagnosis.

STAT · 1d agoRegulatoryNeutral↗ source

Opinion: STAT+: Dementia finally has a business model

The big takeaway from the recent Alzheimer’s Association International Conference in London is an economic message: Dementia finally has a business model, writes Jason Karlawish.

STAT · 1d agoRegulatoryNeutral↗ source

STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD

Biotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.

STAT · 1d agoRegulatoryNeutral↗ source

STAT+: CMS evaluates one year of health tech progress, announces eight new pledge categories

One year after launching the CMS Health Tech Ecosystem, officials convened in D.C. to celebrate the Trump administration modernizing health technology.

STAT · 1d agoRegulatoryNeutral↗ source

ADA faces member backlash and calls for CEO and CSO resignations after expert expulsions

The American Diabetes Association’s 2026 Scientific Sessions in New Orleans ended with the expulsion of five diabetes experts, sparking a wave of criticism. More than 200 members signed an open le…

STAT · 11h agoNegative↗ source

J&J proposes $5.5B talc settlement

After more than a decade and three failed bankruptcy attempts, an end to Johnson & Johnson’s talc saga may finally be in sight. The company has proposed a $5.5 billion settlement ...

Endpoints · 16h agoNeutral↗ source

Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3

💵 Oak Hill Bio’s SPAC merger: The Angelman syndrome biotech will merge with RA Capital’s blank-check company, called Research Alliance Corporation III, and get about ...

Endpoints · 19h agoNeutral↗ source

Alnylam's stock is down 30% despite a booming biotech market. Here's why

Alnylam is one of biopharma’s biggest mysteries so far in 2026. The broader market is seeing a resurgence after years of a bearish environment. M&A is up, IPOs are back with record-breaking force a…

Endpoints · 20h agoNeutral↗ source

Mirae raises $5.4M to turn patient texts into data for doctors

As people increasingly turn to AI chatbots for health questions, one startup wants patients to talk to its chatbot about their symptoms, so their doctors can make better treatment decisions. Mirae,…

Endpoints · 21h agoNeutral↗ source

Eli Lilly tops new biopharma ranking on launch success, development speed

Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global bioph…

Fierce Biotech · 21h agoNeutral↗ source

Claris collects $118M to take eye drop into pivotal testing next year

Claris Bio has a fresh CEO, new board chair and $118 million for two pivotal trials to see if its eye drop can succeed in a blinding disease with no pharmaceutical treatment options. It's a ...

Endpoints · 22h agoNeutral↗ source

Updated: GSK reveals three-year blueprint to cut costs and propel R&D

Just a little over six months into his tenure as CEO at GSK, Luke Miels is making his mark. The drugmaker on Tuesday outlined plans for a three-year cost-cutting initiative, the launch of at least ...

Endpoints · 23h agoNeutral↗ source

Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism

Altimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 RECLAIM trial took a wee…

Endpoints · 23h agoNeutral↗ source

Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options

Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.

Fierce Biotech · 1d agoNeutral↗ source

Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win

An experimental drug targeting both GLP-1 and glucagon receptors has curbed heavy drinking in a phase 2 trial, providing hope that the ubiquitous weight loss meds can be effectively harnessed again…

Fierce Biotech · 1d agoNeutral↗ source

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…

Fierce Biotech · 1d agoNeutral↗ source

Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial

Atea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment regimen.

Fierce Biotech · 1d agoNeutral↗ source

Acrosian debuts as AI-focused biometrics CRO

The founders of contract research organization Quartesian have reunited to form Acrosian, a CRO designed to be purpose-built for the AI era.

Fierce Biotech · 1d agoNeutral↗ source

Guardant Health taps Patrick Dempsey for emotional colorectal cancer awareness video

Colorectal cancer blood test maker Guardant Health has teamed up with “Grey’s Anatomy” star Patrick Dempsey for a new, highly emotional video.

Fierce Biotech · 1d agoNeutral↗ source

GSK partner Hansoh reports another phase 3 win for priority ADC

Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate to another phase 3 win in China.

Fierce Biotech · 1d agoNeutral↗ source

Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pill

Plus news about Outlook Therapeutics, Gossamer Bio, Apnimed and Entera Bio. 📈 Yarrow closes merger to go public: Yarrow Bioscience is developing an anti-TSHR antibody for Graves’ disease and thyro…

Endpoints · 1d agoApprovalPositive↗ source

Otsuka’s ADHD approval opens up new drug class with $615M opportunity

Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.

BioSpace · 1d agoApprovalPositive↗ source